TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22155755

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg at weeks 0, 2, and 6
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infliximab every 8 weeks (q8w)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Infliximab every 12 weeks (q12w)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall remission rate
Number of subjects: 60
Study: 20227541

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol administration intervals between 0 and 72 hours
Number of subjects: 5139

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol administration intervals less than 8 hours
Number of subjects: 5139

Group type: COMPARATOR
Intervention: Longer administration intervals (greater than 8 hours)
Number of subjects: 5139
Study: 18090070

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.5 mg/kg bolus, followed by 4 microg/kg/min infusion)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (saline, equal volume)
Number of subjects: 34
Study: 15145973

Group type: EXPERIMENTAL
Intervention: Lumiracoxib (400 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11920261

Group type: EXPERIMENTAL
Intervention: Conventional first-line chemotherapy (ACVBP)
Number of subjects: 810

Group type: COMPARATOR
Intervention: Alternating chemotherapy regimen (VIMMM with ACVBP for induction and VIM and ACVM in consolidation)
Number of subjects: 810
Study: 9825369

Group type: EXPERIMENTAL
Intervention: i.v. propafenone, 2 mg/kg bolus, followed by 0.0078 mg/kg/min
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: p.o. propafenone, 600 mg p.o. in a single dose
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: p.o. flecainide, 300 mg p.o. in a single dose
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: i.v. amiodarone, 5 mg/kg bolus, followed by 1.8 g/24 hours
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 8085430

Group type: EXPERIMENTAL
Intervention: Neurotropin
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 2655044

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day, 40 mg single dose, 20 mg twice a day)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg/day)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 134
Study: 905090

Group type: EXPERIMENTAL
Intervention: Alcohol at .05 blood alcohol concentration
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alcohol at .10 blood alcohol concentration
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Spurious performance feedback (fast, average, slow RTs)
Number of subjects: 15
Study: 31740463

Group type: EXPERIMENTAL
Intervention: Breastfeeding policy change (Tshwane Declaration of Support for Breastfeeding in South Africa) implemented in 2011
Number of subjects: 10108
Study: 28129308

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bupropion augmentation
Number of subjects: 103
Study: 26264812

Group type: EXPERIMENTAL
Intervention: 80% basal rate (BR) reduction during moderate exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pump stopped during intense exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50% basal rate (BR) reduction during moderate exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 80% basal rate (BR) reduction during intense exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bolus reduction after early post-lunch exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mean blood glucose after 30 min of exercise
Number of subjects: 20
Study: 22248871

Group type: EXPERIMENTAL
Intervention: Valsartan/hydrochlorothiazide (160/12.5 mg titrated to 320/25 mg)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Amlodipine/hydrochlorothiazide (5 mg and 10 mg of amlodipine added at weeks 8 and 12)
Number of subjects: 338
Study: 20591625

Group type: EXPERIMENTAL
Intervention: Creatine (0.03 g · kg(‐1) · d(‐1); n = 10, 4 women)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 10, 4 women)
Number of subjects: 20
Study: 19998583

Group type: EXPERIMENTAL
Intervention: Fixed dose combination tablet of lamivudine and stavudine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Concurrent administration of lamivudine tablet and stavudine capsule
Number of subjects: 24
Study: 17129653

Group type: EXPERIMENTAL
Intervention: Lower-frequency information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher-frequency information
Number of subjects: 0
Study: 15687112

Group type: EXPERIMENTAL
Intervention: Low bicarbonate (LB; 27 mmol/l)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Standard bicarbonate (SB; 35 mmol/l)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High bicarbonate (HB; 39 mmol/l)
Number of subjects: 8
Study: 12031750

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 75 mg (Group D)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 60 mg (Group K)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 102
Study: 10086794

Group type: EXPERIMENTAL
Intervention: GM‐CSF 250 microg/m2 for 3 days followed by G‐CSF 10 microg/kg for 3 days (GM+G)
Number of subjects: 30

Group type: COMPARATOR
Intervention: G‐CSF 10 microg/kg for 6 days (G‐alone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intermediate-dose melphalan (IDM 100 mg/m2)
Number of subjects: 30
Study: 20952898

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topical acyclovir cream
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 2247350

Group type: EXPERIMENTAL
Intervention: ioversol
Number of subjects: 146

Group type: COMPARATOR
Intervention: iopamidol
Number of subjects: 146
Study: 35135

Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intragastric antacid instillation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasogastric suction
Number of subjects: 12
Study: 29685719

Group type: EXPERIMENTAL
Intervention: Purse String Suture (PSS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual Pressure
Number of subjects: 200
Study: 27673483

Group type: EXPERIMENTAL
Intervention: HAEC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HARES
Number of subjects: 0
Study: 25705339

Group type: EXPERIMENTAL
Intervention: Hyaluronidase added to selective nerve root block (SNRB) regimen
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group (SNRB without hyaluronidase)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Both groups (H and C)
Number of subjects: 252
Study: 23320877

Group type: EXPERIMENTAL
Intervention: Four implants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Six implants
Number of subjects: 50
Study: 21900786

Group type: EXPERIMENTAL
Intervention: 4-l polyethylene glycol (PEG) solution (Klean-prep)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: 2-l PEG solution + ascorbic acid (Moviprep)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: sodium phosphate (NaP) solution, Phosphoral
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: simethicone (Aeropax)
Number of subjects: 461
Study: 19551403

Group type: EXPERIMENTAL
Intervention: Isometric elbow flexions at 20, 30, 40, 50, and 60% of maximal voluntary contraction
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EMG amplitude data plotted as function of time for five submaximal bouts
Number of subjects: 8

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 8
Study: 18181314

Group type: EXPERIMENTAL
Intervention: Axillary space closure by suturing the skin flap to the underlying muscle (study group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional wound closure (control group)
Number of subjects: 16
Study: 15008996

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen (CEE) 0.625 mg/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Droloxifene 60 mg/day
Number of subjects: 31
Study: 11426524

Group type: EXPERIMENTAL
Intervention: ABLC (3-5 mg/kg/day for 10 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: AmBisome (3-5 mg/kg/day for 15 days)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ABLC
Number of subjects: 75

Group type: COMPARATOR
Intervention: AmBisome
Number of subjects: 75
Study: 10971989

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings (DuoDERM CGF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline gauze dressings
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cost evaluation of hydrocolloid dressings
Number of subjects: 34
Study: 7527187

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA) using FITC-anti-FITC amplification system
Number of subjects: 135
Study: 2692092

Group type: EXPERIMENTAL
Intervention: High dose inhaled beclomethasone dipropionate (2000 micrograms day‐1 for two weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1192701

Group type: EXPERIMENTAL
Intervention: Oral sodium loading (100 mmol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous sodium loading (100 mmol)
Number of subjects: 0
Study: 30734413

Group type: EXPERIMENTAL
Intervention: Lidocaine spray (10% lidocaine, 8 puffs, 80 mg total, 3 minutes before procedure)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo spray (0.8 mL normal saline, 3 minutes before procedure)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 240
Study: 26057917

Group type: EXPERIMENTAL
Intervention: Torus mandibularis bone graft
Number of subjects: 14

Group type: COMPARATOR
Intervention: Full-thickness flap alone
Number of subjects: 14
Study: 24152688

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 21636546

Group type: EXPERIMENTAL
Intervention: Oral iloprost
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 19321590

Group type: EXPERIMENTAL
Intervention: Low-glycemic index (LGI) breakfast
Number of subjects: 8

Group type: COMPARATOR
Intervention: High-glycemic index (HGI) breakfast
Number of subjects: 8
Study: 16490478

Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/day for 10 consecutive days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Diazepam (0.5-0.75 mg/kg/day for 6 consecutive days, tapering the dose by 25% daily from day 7 to day 10)
Number of subjects: 37
Study: 15589641

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 102
Study: 11421996

Group type: EXPERIMENTAL
Intervention: Intravenous administration of BDP (1000 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled BDP (1000 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral BDP (4000 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intranasal BDP (1344 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled BDP with charcoal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral and intranasal BDP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled BDP
Number of subjects: 12
Study: 9546759

Group type: EXPERIMENTAL
Intervention: New individually controlled ventilation system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 7690935

Group type: EXPERIMENTAL
Intervention: RAMP pacing
Number of subjects: 31

Group type: COMPARATOR
Intervention: BURST pacing
Number of subjects: 31
Study: 3739593

Group type: EXPERIMENTAL
Intervention: GK-esophageal thermal tube with circulating 41.7 degrees C warm water (Group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No active warming (Group B)
Number of subjects: 33
Study: 29132159

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470
Study: 27013431

Group type: EXPERIMENTAL
Intervention: High dose + adjuvant (100 μg antigen + AlOH)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: High dose + adjuvant (100 μg antigen + AlOH) administered on Days 0-7-30
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Low dose (50 μg antigen) with or without aluminum hydroxide (AlOH) adjuvant
Number of subjects: 661
Study: 24998111

Group type: EXPERIMENTAL
Intervention: 2 μg kg(‐1) remifentanil (Group 1, n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 μg kg(‐1) remifentanil and 1 mg kg(‐1) lidocaine (Group 2, n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 μg kg(‐1) remifentanil (Group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 μg kg(‐1) remifentanil and 1 mg kg(‐1) lidocaine (Group 2)
Number of subjects: 50
Study: 22951598

Group type: EXPERIMENTAL
Intervention: Aerobic training for 1 h 3 times per week at 70% of maximal exercise capacity
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study: 20861583

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30-70 mg/day
Number of subjects: 127
Study: 18754762

Group type: EXPERIMENTAL
Intervention: Melatonin mixed with soft food and liquids (water, orange juice, semi-skimmed milk, strawberry yogurt, and strawberry jam)
Number of subjects: 0
Study: 16161955

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 115

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 115
Study: 12559244

Group type: EXPERIMENTAL
Intervention: Peripheral repetitive magnetic stimulation (rMS) - 10 sessions, each lasting 20 minutes, with 4000 magnetic stimuli administered in 5s trains at 20Hz at the trigger point.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment - application of a non-functioning ultrasound therapy device to the trigger point.
Number of subjects: 18
Study: 12270857

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) users
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 9618771

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (observational data)
Number of subjects: 0
Study: 8039873

Group type: EXPERIMENTAL
Intervention: HibCP coupled to tetanus toxoid (TT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HibCP coupled to diphtheria toxoid (DT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TT alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DT alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HibCP AbSC in adults
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preimmunization level of natural HibCP antibodies
Number of subjects: 60
Study: 3282480

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 481

Group type: COMPARATOR
Intervention: Subjects with current MDE
Number of subjects: 481

Group type: COMPARATOR
Intervention: Presence of depression and degree of phobic avoidance
Number of subjects: 481
Study: 30962235

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sham-EA
Number of subjects: 110
Study: 28337876

Group type: EXPERIMENTAL
Intervention: Secnidazole
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Proanthocyanidins
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 75
Study: 26456134

Group type: EXPERIMENTAL
Intervention: d-Cycloserine (125mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 24151766

Group type: EXPERIMENTAL
Intervention: Cinacalcet and low doses of vitamin D analogs
Number of subjects: 235

Group type: COMPARATOR
Intervention: Larger, varying doses of vitamin D
Number of subjects: 235
Study: 21609245

Group type: EXPERIMENTAL
Intervention: Lekker Fit! intervention (multi-component intervention with 3 PE sessions a week, additional sport and play activities, educational program)
Number of subjects: 2622

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2622

Group type: EXPERIMENTAL
Intervention: Lekker Fit! intervention (multi-component intervention)
Number of subjects: 2622
Study: 18751702

Group type: EXPERIMENTAL
Intervention: Autologous conditioned serum (ACS) containing endogenous anti-inflammatory cytokines including IL-1Ra and several growth factors (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 20
Study: 16784346

Group type: EXPERIMENTAL
Intervention: Lower starting prices in auctions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Barriers to entry (e.g., misspelled brand name)
Number of subjects: 0
Study: 15303768

Group type: EXPERIMENTAL
Intervention: Radiotherapy + paclitaxel (30 mg/m2 weekly, median six cycles)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Radiotherapy + paclitaxel (60 mg/m2 weekly, median six cycles)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Radiotherapy + paclitaxel
Number of subjects: 21
Study: 11528489

Group type: EXPERIMENTAL
Intervention: Classic preterm formula (group P)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Regular formula (term group T)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Formula with AA and DHA (group PB)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Formula with AA and DHA (group PA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All preterm groups (P, PA, PB)
Number of subjects: 42
Study: 9524874

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Elective orthopaedic surgery (Control)
Number of subjects: 28
Study: 8320402

Group type: EXPERIMENTAL
Intervention: Healthy Food Choices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exchange systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate counting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total available glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavior management approaches
Number of subjects: 0
Study: 31092122

Group type: EXPERIMENTAL
Intervention: Recurrent low back pain group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 38
Study: 28625627

Group type: EXPERIMENTAL
Intervention: Toxicity-Adjusted Dosing (TAD) of cisplatin + etoposide
Number of subjects: 158

Group type: COMPARATOR
Intervention: Fixed Dosing (FD) of cisplatin + etoposide
Number of subjects: 158
Study: 26251244

Group type: EXPERIMENTAL
Intervention: 70 μg/kg desmoteplase
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 90 μg/kg desmoteplase
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 23052033

Group type: EXPERIMENTAL
Intervention: ACT-077825 (500 mg, 1000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-077825 (500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACT-077825 (1000 mg)
Number of subjects: 0
Study: 22073219

Group type: EXPERIMENTAL
Intervention: Eplerenone (25-50 mg once daily for 8 weeks)
Number of subjects: 40
Study: 18926569

Group type: EXPERIMENTAL
Intervention: Dispersible artemether-lumefantrine tablets
Number of subjects: 899

Group type: COMPARATOR
Intervention: Crushed artemether-lumefantrine tablets
Number of subjects: 899
Study: 16446752

Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG) 8 mg
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG) 2 mg
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG) 4 mg
Number of subjects: 511

Group type: COMPARATOR
Intervention: rosiglitazone (RSG) 2, 4, or 8 mg
Number of subjects: 511
Study: 12587890

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) ingestion (0.3 g x kg body mass(-1))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10694768

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) spaghetti meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: High‐GI white wheat bread (WWB) reference meal
Number of subjects: 10
Study: 9096584

Group type: EXPERIMENTAL
Intervention: Netilmicin plus mezlocillin
Number of subjects: 128

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 128
Study: 8213103

Group type: EXPERIMENTAL
Intervention: EE/NET formulation (EE 35 micrograms and norethisterone 0.5 mg on days 1‐7 and days 17‐21, elevated to 1.0 mg during days 8‐16)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: EE/LGN formulation (EE 30 micrograms on days 1‐6 and days 12‐21, 40 micrograms on days 7‐11, phased levonorgestrel: 50 micrograms (days 1‐6), 75 micrograms (days 7‐11), and 125 micrograms (days 12‐21)
Number of subjects: 196
Study: 3777330

Group type: EXPERIMENTAL
Intervention: Gentamicin (single dose)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 176
Study: 30572916

Group type: EXPERIMENTAL
Intervention: One cycle of GnRH agonist
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Two cycles of GnRH agonist
Number of subjects: 421
Study: 27793181

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT) programme FearFighter™, nine sessions with weekly telephone contact
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy (ICBT) programme FearFighter™
Number of subjects: 64

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 64
Study: 24628464

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22031515

Group type: EXPERIMENTAL
Intervention: Total thyroid ablation (thyroidectomy plus (131)I)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Thyroidectomy (TX)
Number of subjects: 52
Study: 20696074

Group type: EXPERIMENTAL
Intervention: Laser Doppler imaging (LDI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fingertip lacticemy (FTL)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy (NFC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cold stimulus (CS)
Number of subjects: 44